Compare iShares MSCI South Korea ETF (EWY) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs IDEXX Laboratories, Inc. — how do they compare? iShares MSCI South Korea ETF trades at $177.22 (market cap $26.25B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EWY | IDXX | |
|---|---|---|
Market Cap | $26.25B | $40.43B |
Volume | 19,056,075 | 692,164 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $766.68 |
52-Week Low | $80.72 | $504.70 |
Typical Hold Time | 47 Days | 46 Days |
Enterprise Value | — | $41.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY is trading at $176.33, down 4.02% amid bearish technical signals, with moving averages indicating selling pressure. The ETF faces headwinds from rising US yields and oil prices impacting South Korean tech stocks, though RSI levels suggest potential oversold conditions. Recent volatility reflects sensitivity to AI sector dynamics and global macroeconomic factors.
Outlook remains cautious due to concentrated exposure to semiconductor giants Samsung and SK Hynix, creating dependency on memory cycle strength. Investment opportunity exists if AI demand sustains earnings growth, but risks include Fed policy impacts and geopolitical tensions. Governance reforms and deleveraging provide fundamental support amid market turbulence.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
